Evidence map›Paper›PMID 41613425›Full record

ReviewFundamental research2025

The application of antibody-based agents in cancer therapy based on their mechanisms of action.

Kewen Qian, Guangyao Li, Shuyi Zhang, Yitan Zou, Hongru Ai, Xinya Zheng, Wenyan Fu, Changhai Lei, Shi Hu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Fundamental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kewen QianDepartment of Biomedical Engineering, College of Basic Medical Sciences, Second Military Medical University, Shanghai 200433, China.
Guangyao LiDepartment of Biophysics, College of Basic Medical Sciences, Second Military Medical University, Shanghai 200433, China.
Shuyi ZhangDepartment of Biophysics, College of Basic Medical Sciences, Second Military Medical University, Shanghai 200433, China.
Yitan ZouDepartment of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Second Military Medical University, Shanghai 200433, China.
Hongru AiDepartment of Biomedical Engineering, College of Basic Medical Sciences, Second Military Medical University, Shanghai 200433, China.
Xinya ZhengDepartment of Biomedical Engineering, College of Basic Medical Sciences, Second Military Medical University, Shanghai 200433, China.
Wenyan FuDepartment of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.
Changhai LeiDepartment of Biophysics, College of Basic Medical Sciences, Second Military Medical University, Shanghai 200433, China.
Shi HuDepartment of Biomedical Engineering, College of Basic Medical Sciences, Second Military Medical University, Shanghai 200433, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal antibodies and antibody-based agents are undergoing remarkable development in cancer immunotherapy. Based on their structural components, these antibodies mediate the crosslinking of tumor cells and the immune system, enabling specific antigen targeting and broad immune responses. Novel engineering strategies are aimed at improving both specificity and affinity of antigen recognition and enhancing the recruitment and activation of immune cells. Antibody-based therapeutics have been expanded for use in combination with other immunotherapies such as cellular immunotherapy and therapeutic vaccines. In this review, we provide comprehensive updates on the ongoing clinical development and evolving practices in the field, with a specific emphasis on the intricate mechanisms of action.

Indexed as

Antibody-drug conjugatesAntibody therapyCancer therapyImmunotherapyMonoclonal antibodies

Identifiers

PMID41613425
PMCPMC12848217

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.